China’s Health Insurance Premiums Up 26% In First Half
This article was originally published in PharmAsia News
The China Insurance Regulatory Commission’s statistics revealed that from January to June, total health insurance premiums in China increased 26% or RMB 9.84 billion to RMB 46.62 billion.
You may also be interested in...
Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.
Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.